Another week, another round of developments across psychedelic medicine. Below is our recap of what mattered to investors for the week of May 25–31, 2026.
GH Research PLC (GHRS): GH Research showcases Phase 2b GH001 posters at ASCP annual meeting
At the ASCP annual meeting (May 26-29 in Miami), GH Research presented three posters from its Phase 2b treatment-resistant depression trial of inhaled mebufotenin (GH001). The data showed rapid, clinically meaningful reductions in depression and anhedonia versus placebo at Day 8, with benefits maintained through a six-month open-label extension and efficacy appearing independent of the number of prior antidepressant failures. The presentations reinforce the profile of GH001 ahead of pivotal Phase 3 work.
Source: stocktitan.net
Optimi Health Corp. (OPTH): Optimi Health welcomes expanded Australian Authorized Prescriber framework for psilocybin and MDMA
Optimi Health highlighted final recommendations from Australia's Therapeutic Goods Administration that broaden the Authorized Prescriber scheme for psilocybin (for treatment-resistant depression) and MDMA (for PTSD), widening therapist eligibility and accepted treatment settings. Optimi supplies both products into Australia from its GMP facility in Canada. The expansion supports demand for the company's finished psychedelic drug products in the world's leading regulated prescription market, where coverage now spans private insurers and public schemes such as the DVA and NDIS.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.